Cellarity, Inc.

Robert Brian Nicewonger

Atli Thorarensen

Na Li

Mauricio Cortes

Kristen Marino

David Zhang

Colin Diner

Samuel Miller

Frank Lovering

Ravi Ujjinamatada

Qing Tang

Ragy Haddad

The present disclosure provides DCN-1 modulating compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions, and their use for treating sickle cell disorders, diseases, and conditions. Such compounds are of Formula I: or a pharmaceutically acceptable salt thereof.

DCN-1 modulating compounds and methods of use thereof

The present disclosure provides DCN-1 modulating compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions, and their use for treating sickle cell disorders, diseases, and conditions. Such compounds are of Formula Ia: or a pharmaceutically acceptable salt thereof.

Modulators of DCN-1 and methods of use thereof

Growing community of inventors

Tyngsboro, MA, United States of America

Robert Brian Nicewonger